JP2023524789A - Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ - Google Patents

Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ Download PDF

Info

Publication number
JP2023524789A
JP2023524789A JP2022567419A JP2022567419A JP2023524789A JP 2023524789 A JP2023524789 A JP 2023524789A JP 2022567419 A JP2022567419 A JP 2022567419A JP 2022567419 A JP2022567419 A JP 2022567419A JP 2023524789 A JP2023524789 A JP 2023524789A
Authority
JP
Japan
Prior art keywords
day
egfr
pharmaceutically acceptable
amino
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524789A5 (https=
Inventor
ハオ，フアシャン
リウ，チェン
イー． ムーディー，スーザン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023524789A publication Critical patent/JP2023524789A/ja
Publication of JP2023524789A5 publication Critical patent/JP2023524789A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022567419A 2020-05-08 2021-05-06 Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ Pending JP2023524789A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063021772P 2020-05-08 2020-05-08
US63/021,772 2020-05-08
US202063117388P 2020-11-23 2020-11-23
US63/117,388 2020-11-23
PCT/IB2021/053867 WO2021224867A1 (en) 2020-05-08 2021-05-06 Pharmaceutical combination comprising tno155 and nazartinib

Publications (2)

Publication Number Publication Date
JP2023524789A true JP2023524789A (ja) 2023-06-13
JP2023524789A5 JP2023524789A5 (https=) 2024-05-16

Family

ID=75904981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567419A Pending JP2023524789A (ja) 2020-05-08 2021-05-06 Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ

Country Status (12)

Country Link
US (1) US20230172928A1 (https=)
EP (1) EP4146217A1 (https=)
JP (1) JP2023524789A (https=)
KR (1) KR20230008719A (https=)
CN (1) CN115397421A (https=)
AU (1) AU2021267213B2 (https=)
BR (1) BR112022022305A2 (https=)
CA (1) CA3179994A1 (https=)
IL (1) IL297043A (https=)
MX (1) MX2022013867A (https=)
TW (1) TW202207933A (https=)
WO (1) WO2021224867A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112867718B (zh) 2018-09-29 2025-03-04 诺华股份有限公司 用于抑制shp2活性的化合物和组合物的制造
IL305106B2 (en) 2018-09-29 2025-08-01 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
US12441737B2 (en) 2020-07-08 2025-10-14 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of SHP2
US20250127782A1 (en) 2021-09-08 2025-04-24 Amgen Inc. Methods of treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065453A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CA3048340A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065453A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIEL S-W TAN ET AL.: ""Safety and efficacyof nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lungcarcinoma:", THE LANCET RESPIRATORY MEDICINE, vol. 8, no. 6, JPN6026002790, 15 January 2020 (2020-01-15), pages 561 - 572, ISSN: 0005787170 *
HUAIXIANG HAO ET AL.: ""Abstract LB-122: Combinations of SHP2 inhibitor to overcome RASactivation by receptor tyrosine kin", CANCER RESEARCH, vol. Vol. 80, No. 16_Supplement, JPN6025016257, 15 August 2020 (2020-08-15), pages 122 - 122, ISSN: 0005583744 *

Also Published As

Publication number Publication date
BR112022022305A2 (pt) 2022-12-20
CA3179994A1 (en) 2021-11-11
MX2022013867A (es) 2022-11-30
AU2021267213B2 (en) 2023-11-30
AU2021267213A1 (en) 2022-11-03
CN115397421A (zh) 2022-11-25
EP4146217A1 (en) 2023-03-15
US20230172928A1 (en) 2023-06-08
IL297043A (en) 2022-12-01
WO2021224867A1 (en) 2021-11-11
KR20230008719A (ko) 2023-01-16
TW202207933A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
JP7572958B2 (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
CN115297862A (zh) 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
US11298362B2 (en) Combination therapy with Notch and CDK4/6 inhibitors for the treatment of cancer
JP2020529411A (ja) 第三世代ｅｇｆｒチロシンキナーゼ阻害剤とｒａｆ阻害剤の治療用組合せ
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of
HK40004472A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
HK40004472B (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203